BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37109459)

  • 21. Cryopreservation of in vitro matured oocytes in addition to ovarian tissue freezing for fertility preservation in paediatric female cancer patients before and after cancer therapy.
    Abir R; Ben-Aharon I; Garor R; Yaniv I; Ash S; Stemmer SM; Ben-Haroush A; Freud E; Kravarusic D; Sapir O; Fisch B
    Hum Reprod; 2016 Apr; 31(4):750-62. PubMed ID: 26848188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combining fertility preservation procedures to spread the eggs across different baskets: a feasibility study.
    Delattre S; Segers I; Van Moer E; Drakopoulos P; Mateizel I; Enghels L; Tournaye H; De Vos M
    Hum Reprod; 2020 Nov; 35(11):2524-2536. PubMed ID: 32951035
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Other Primary Malignancies in Patients with Breast Cancer Who Undergo Germline Panel Testing.
    Murphy BL; Yi M; Gutierrez Barrera AM; Tripathy D; Hunt KK; Arun BK
    Ann Surg Oncol; 2023 Mar; 30(3):1663-1668. PubMed ID: 36094691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits.
    Wu HL; Luo ZY; He ZL; Gong Y; Mo M; Ming WK; Liu GY
    Br J Cancer; 2023 Feb; 128(4):638-646. PubMed ID: 36564566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Knowledge, acceptability and personal attitude toward pre-implantation 1 genetic testing (PGT) and pre-natal diagnosis (PND) for females carrying BRCA pathogenic variant according to fertility preservation experience.
    Dervin T; Ranisavjevic N; Laot L; Mayeur A; Duperier C; Steffann J; Borghese R; Stoppa-Lyonnet D; Frydman N; Benachi A; Sonigo C; Grynberg M
    J Assist Reprod Genet; 2023 Jun; 40(6):1381-1390. PubMed ID: 37154838
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
    Engel C; Rhiem K; Hahnen E; Loibl S; Weber KE; Seiler S; Zachariae S; Hauke J; Wappenschmidt B; Waha A; Blümcke B; Kiechle M; Meindl A; Niederacher D; Bartram CR; Speiser D; Schlegelberger B; Arnold N; Wieacker P; Leinert E; Gehrig A; Briest S; Kast K; Riess O; Emons G; Weber BHF; Engel J; Schmutzler RK;
    BMC Cancer; 2018 Mar; 18(1):265. PubMed ID: 29514593
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ovarian Stimulation in Patients With Cancer: Impact of Letrozole and BRCA Mutations on Fertility Preservation Cycle Outcomes.
    Turan V; Bedoschi G; Emirdar V; Moy F; Oktay K
    Reprod Sci; 2018 Jan; 25(1):26-32. PubMed ID: 28874104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of controlled ovarian hyperstimulation with or without letrozole for fertility preservation in breast cancer patients: A multicenter retrospective study.
    Goldrat O; De Cooman M; Mailliez A; Delbaere A; D'Orazio E; Demeestere I; Decanter C
    Eur J Cancer; 2022 Oct; 174():134-141. PubMed ID: 35998549
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response to ovarian stimulation is not impacted by a breast cancer diagnosis.
    Quinn MM; Cakmak H; Letourneau JM; Cedars MI; Rosen MP
    Hum Reprod; 2017 Mar; 32(3):568-574. PubMed ID: 28122888
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fertility preservation in female oncology patients: the influence of the type of cancer on ovarian stimulation response.
    Alvarez RM; Ramanathan P
    Hum Reprod; 2018 Nov; 33(11):2051-2059. PubMed ID: 27370358
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BRCA1 mutation carriers have a lower number of mature oocytes after ovarian stimulation for IVF/PGD.
    Derks-Smeets IAP; van Tilborg TC; van Montfoort A; Smits L; Torrance HL; Meijer-Hoogeveen M; Broekmans F; Dreesen JCFM; Paulussen ADC; Tjan-Heijnen VCG; Homminga I; van den Berg MMJ; Ausems MGEM; de Rycke M; de Die-Smulders CEM; Verpoest W; van Golde R
    J Assist Reprod Genet; 2017 Nov; 34(11):1475-1482. PubMed ID: 28831696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does type of cancer affect ovarian response in oncofertility patients?
    Hussein RS; Zhao Y; Khan Z
    J Gynecol Obstet Hum Reprod; 2021 Jun; 50(6):101944. PubMed ID: 33069914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ovarian reserve of women with and without BRCA pathogenic variants: A systematic review and meta-analysis.
    Gasparri ML; Di Micco R; Zuber V; Taghavi K; Bianchini G; Bellaminutti S; Meani F; Graffeo R; Candiani M; Mueller MD; Papadia A; Gentilini OD
    Breast; 2021 Dec; 60():155-162. PubMed ID: 34627117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of ovarian and breast cancer risk in non-BRCA HBOC pathogenic variant carriers in a large California health care system.
    Powell CB; Laurent C; Garcia C; Hoodfar E; Karlea A; Kobelka C; Lee J; Roh J; Kushi LH
    Gynecol Oncol; 2022 Dec; 167(3):467-475. PubMed ID: 36220669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum antimüllerian hormone is associated with the number of oocytes matured in vitro and with primordial follicle density in candidates for fertility preservation.
    Sermondade N; Sonigo C; Sifer C; Valtat S; Ziol M; Eustache F; Grynberg M
    Fertil Steril; 2019 Feb; 111(2):357-362. PubMed ID: 30527837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Systematic proposal of fertility preservation by mature oocyte cryopreservation for recurrent benign ovarian tumors].
    Dadoun Y; Azaïs H; Keller L; d'Orazio E; Collinet P; Decanter C
    Gynecol Obstet Fertil Senol; 2017 Jun; 45(6):359-365. PubMed ID: 28506797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical features of germline BRCA1/2 or ATM pathogenic variant positive pancreatic cancer in Japan.
    Kitamura H; Morizane C; Tanabe N; Go I; Maruki Y; Ohba A; Nagashio Y; Kondo S; Hijioka S; Ueno H; Yoshida T; Okusaka T
    Pancreatology; 2023 Dec; 23(8):964-969. PubMed ID: 37914629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fertility preservation in Turner syndrome: Karyotype does not predict ovarian response to stimulation.
    Vergier J; Bottin P; Saias J; Reynaud R; Guillemain C; Courbiere B
    Clin Endocrinol (Oxf); 2019 Nov; 91(5):646-651. PubMed ID: 31420888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fertility preservation in BRCA mutation carriers-efficacy and safety issues: a review.
    Zhang X; Niu J; Che T; Zhu Y; Zhang H; Qu J
    Reprod Biol Endocrinol; 2020 Feb; 18(1):11. PubMed ID: 32070378
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predicting the likelihood of live birth for elective oocyte cryopreservation: a counseling tool for physicians and patients.
    Goldman RH; Racowsky C; Farland LV; Munné S; Ribustello L; Fox JH
    Hum Reprod; 2017 Apr; 32(4):853-859. PubMed ID: 28166330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.